Adaptive Biotechnologies Corp Stock Market Capitalization
| ADPT Stock | USD 2.60 0.02 0.78% |
Adaptive Biotechnologies Corp fundamentals help investors to digest information that contributes to Adaptive Biotechnologies' financial success or failures. It also enables traders to predict the movement of Adaptive Stock. The fundamental analysis module provides a way to measure Adaptive Biotechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Adaptive Biotechnologies stock.
Adaptive |
Adaptive Biotechnologies Corp Company Market Capitalization Analysis
Adaptive Biotechnologies' Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current Adaptive Biotechnologies Market Capitalization | 374.34 M |
Most of Adaptive Biotechnologies' fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adaptive Biotechnologies Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
| Competition |
Based on the recorded statements, the market capitalization of Adaptive Biotechnologies Corp is about 374.34 M. This is 97.11% lower than that of the Life Sciences Tools & Services sector and 92.1% lower than that of the Health Care industry. The market capitalization for all United States stocks is 98.03% higher than that of the company.
Adaptive Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adaptive Biotechnologies' direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adaptive Biotechnologies could also be used in its relative valuation, which is a method of valuing Adaptive Biotechnologies by comparing valuation metrics of similar companies.Adaptive Biotechnologies is currently under evaluation in market capitalization category among related companies.
Adaptive Fundamentals
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (1.32) % | ||||
| Operating Margin | (1.00) % | ||||
| Current Valuation | 257.25 M | ||||
| Shares Outstanding | 145.09 M | ||||
| Shares Owned By Insiders | 2.80 % | ||||
| Shares Owned By Institutions | 95.84 % | ||||
| Number Of Shares Shorted | 9.1 M | ||||
| Price To Earning | 0.25 X | ||||
| Price To Book | 1.42 X | ||||
| Price To Sales | 2.56 X | ||||
| Revenue | 170.28 M | ||||
| Gross Profit | (13.66 M) | ||||
| EBITDA | (179.38 M) | ||||
| Net Income | (225.25 M) | ||||
| Cash And Equivalents | 383.74 M | ||||
| Cash Per Share | 2.69 X | ||||
| Total Debt | 229.43 M | ||||
| Debt To Equity | 0.21 % | ||||
| Current Ratio | 3.93 X | ||||
| Book Value Per Share | 2.13 X | ||||
| Cash Flow From Operations | (156.32 M) | ||||
| Short Ratio | 5.80 X | ||||
| Earnings Per Share | (1.56) X | ||||
| Target Price | 6.4 | ||||
| Number Of Employees | 709 | ||||
| Beta | 1.24 | ||||
| Market Capitalization | 374.34 M | ||||
| Total Asset | 661.13 M | ||||
| Retained Earnings | (1.14 B) | ||||
| Working Capital | 322.17 M | ||||
| Current Asset | 118.69 M | ||||
| Current Liabilities | 59.26 M | ||||
| Net Asset | 661.13 M |
About Adaptive Biotechnologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adaptive Biotechnologies Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adaptive Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adaptive Biotechnologies Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Adaptive Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptive Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptive Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving together with Adaptive Stock
| 0.62 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.72 | DRMA | Dermata Therapeutics Financial Report 9th of May 2024 | PairCorr |
Moving against Adaptive Stock
| 0.82 | YS | YS Biopharma | PairCorr |
| 0.73 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.73 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.68 | DSGN | Design Therapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.68 | FUSN | Fusion PharmaceuticalsInc Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to Adaptive Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptive Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptive Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptive Biotechnologies Corp to buy it.
The correlation of Adaptive Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptive Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptive Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptive Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Adaptive Biotechnologies Piotroski F Score and Adaptive Biotechnologies Altman Z Score analysis. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for Adaptive Stock analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptive Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.